Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Sonya Reid, MD, MPH, discusses barriers to universal germline testing utilization in breast cancer, particularly among underserved populations.
Research Propels Additional Options into the Advanced HER2+ Breast Cancer Armamentarium
Sarah Sammons, MD, discusses the evolving treatment landscape for metastatic HER2-postive breast cancer.
Research With ctDNA Continues to Pave the Way Toward Optimal Breast Cancer Management
July 22nd 2024Circulating tumor DNA is in constant flux, rendering its evaluation potentially useful in metastatic breast cancer management.
Sara M. Tolaney, MD, MPH, discusses the use of HER2-directed therapy in the curative setting for HER2-positive breast cancer.
Dr Feldman on New Approaches for Decreasing the Risk of Breast Cancer–Related Lymphedema
July 20th 2024Sheldon Feldman, MD discusses new approaches for decreasing the risk of and managing breast cancer¬–related lymphedema.
Dr Mukhtar on Challenges in the Diagnosis and Management of Invasive Lobular Carcinoma
July 20th 2024Rita Mukhtar, MD, discusses challenges in the diagnosis and management of invasive lobular carcinoma.
Dr Pusztai on Molecular Residual Disease Monitoring in Early Breast Cancer
July 20th 2024Lajos Pusztai, MD, DPhil, discusses the progress and challenges in monitoring molecular residual disease in early breast cancer.
AE Management and Prevention Strategies for ADCs, Immunotherapy in Breast Cancer
Hope Rugo, MD, discusses the management of treatment-limiting toxicities in breast cancer, including the use of antibody-drug conjugates and immunotherapy.
Dr Rugo on Managing Treatment-Limiting Toxicities in Breast Cancer
July 19th 2024Hope S. Rugo, MD discusses managing treatment-related toxicities within the scope of the current breast cancer treatment paradigm.
ASCO 2024 Data Shake Up Standards and Shed Light on Biomarkers
July 16th 2024This roundup includes exclusive insights from nearly 20 clinicians and key data on the top abstracts coming out of the 2024 ASCO Annual Meeting.
Belzutifan Yields PFS Advantage in Pretreated Advanced ccRCC Across Subgroups
July 12th 2024Belzutifan generated superior efficacy and safety outcomes vs everolimus across prespecified subgroups of patients with previously treated advanced ccRCC.
Abemaciclib Monotherapy Does Not Elicit Responses in Advanced Renal Cell Carcinoma
Treatment with single-agent abemaciclib (Verzenio) did not demonstrate clinically meaningful activity in heavily treated patients with metastatic clear cell renal cell carcinoma.
Fianlimab Plus Cemiplimab Yields Early Efficacy Signs in Pretreated Advanced ccRCC
Fianlimab plus cemiplimab produced durable responses in heavily pretreated advanced clear cell renal cell carcinoma.
Belzutifan Shows Manageable, Pooled Safety Profile in Advanced VHL-Associated RCC
Most patients included in the post-hoc pooled analysis who were treated with belzutifan experienced an all-cause adverse effect.
Dr Semaan on Liquid Biopsy Epigenomic Profiling for the Detection of Sarcomatoid RCC
July 12th 2024Karl Semaan, MD, MSc, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma.
Dr McGregor on the Data for Abemaciclib in Advanced ccRCC
July 12th 2024Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib in clear cell renal cell carcinoma.
Ongoing Research Aims to Identify Treatment Approaches for Non–Clear Cell RCC Subtypes
Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma.
No OS Difference Observed After Various Immunotherapy/TKI Regimens in Advanced RCC
July 12th 2024Real-world treatment patterns demonstrated that similar OS outcomes occurred for patients with renal cell carcinoma who received TKI- and immunotherapy-based regimens.
Dr Choueiri on the Phase 3 TiNivo-2 Study in Pretreated Advanced RCC
July 11th 2024Toni K. Choueiri, MD, discusses the phase 3 TiNivo-2 study in pretreated advanced renal cell carcinoma.
Dr Shah on Remaining Unmet Needs in RCC After Frontline IO Combinations
July 11th 2024Neil J. Shah, MBBS, discusses unmet needs for patients with RCC receiving immune-oncology–based combinations in the frontline setting.
Multimodal AI Approach May Help Identify Key Elements to Predict Outcomes in RCC
July 11th 2024Using an AI tool for the collection and analysis of patient data may enhance the accuracy of outcome predictions and help personalize treatment plans.
Nivolumab Plus Ipilimumab Yields Long-Term Efficacy Advantage in Advanced RCC
Nivolumab plus ipilimumab may generate positive long-term outcomes in patients with advanced renal cell carcinoma regardless of IMDC risk status.
Data from the phase 2 REGINA trial support further investigation of neoadjuvant regorafenib, nivolumab, and SCRT in locally advanced rectal cancer.
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer
Dostarlimab plus chemotherapy demonstrated a meaningful overall survival improvement in primary endometrial cancer, regardless of mismatch repair status.
Perioperative Pembrolizumab/Chemo Regimen Yields Superior OS in Resectable Gastric Cancer
July 2nd 2024Patients with resectable gastric cancers achieved superior OS and pCR rates with perioperative pembrolizumab plus chemotherapy vs chemotherapy alone.
First-Line Tislelizumab Plus Chemotherapy Shows OS Benefit in PD-L1+ ESCC Subgroups
July 2nd 2024Tislelizumab plus chemotherapy improved OS in patients with unresectable esophageal squamous cell carcinoma and a CPS or TAP score of at least 1 vs 1%.
IBI343 Is Safe, Generates Preliminary Efficacy in CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma
IBI343 was well tolerated and demonstrated signs of efficacy in patients with CLDN18.2-positive advanced gastric/GEJ adenocarcinoma.
Mitazalimab/mFOLFIRINOX Is Tolerable, Generates Responses in Treatment-Naive mPDAC
July 2nd 2024Mitazalimab plus mFOLFIRINOX yielded early efficacy signals and a manageable safety profile for the frontline treatment of patients with mPDAC.
Durvalumab Plus Olaparib Approaches EU Approval for pMMR Advanced or Recurrent Endometrial Cancer
The EMA recommends durvalumab plus chemotherapy, followed by olaparib and durvalumab for pMMR endometrial cancer, and single-agent durvalumab for dMMR disease.
Durvalumab Plus Chemo Maintains OS Benefit in Advanced Biliary Tract Cancer
Durvalumab plus chemotherapy sustained an overall survival benefit vs chemotherapy alone in locally advanced or metastatic biliary tract cancer.
